

## Temporal relationship of sleep apnea and acromegaly: a nationwide study

### Endocrine

Konstantina Vouzouneraki\*, Karl A. Franklin, Maria Forsgren, Maria Wärn, Jenny Tiberg Persson, Helena Wik, Christina Dahlgren, Ann-Sofie Nilsson, Caroline Alkebro, Pia Burman, Eva-Marie Erfurth, Jeanette Wahlberg, Anna-Karin Åkerman, Charlotte Høybye, Oskar Ragnarsson, Britt Edén Engström, Per Dahlqvist

\* Corresponding author, Department of Public Health and Clinical Medicine, Umeå University  
e-mail: [konstantina.vouzouneraki@umu.se](mailto:konstantina.vouzouneraki@umu.se)

**Online Resource 1** Characteristics of 95 patients with newly or previously diagnosed sleep apnea and 164 patients without sleep apnea.

	Sleep apnea (n = 95)	No sleep apnea (n = 164)	All (n = 259)
Age in years*	59 (53–67)	58 (45–68)	59 (47–67)
Men, %	55	49	51
Current smokers, valid %, n = 255	15	17	16
Current or previous smokers, valid %, n = 255	51	46	47
Snoring, valid %, n = 253	62	43	50
Partner-observed apneas during sleep, valid %, n = 257	44	15	26
BMI*, kg/m <sup>2</sup>	30 (27–34)	26 (24–30)	28 (25–32)
BMI <25 kg/m <sup>2</sup> , valid %, n = 258	16	36	29
BMI 25–30 kg/m <sup>2</sup> , valid %, n = 258	36	38	37
BMI >30 kg/m <sup>2</sup> , valid %, n = 258	48	26	34
Waist circumference*, cm	104	95	98

	(92–113)	(86–104)	(87–109)
S-IGF-1, % of ULN *	86 (66–120)	78 (63–104)	82 (63–109)
S-IGF-1 ≤ULN, valid %, n = 258	64	71	69
S-IGF-1 in the highest quartile (Q4), %	33	20	25
Hypertension, current treatment, %	53	46	48
Diabetes, current treatment, %	8.4	8.5	8.5
Heart failure, current treatment, valid% n = 258	0	1.8	1.2
Angina Pectoris, current treatment, %	1.1	0.6	0.8
Myocardial infarction, previous, %	1.1	1.2	1.2
Stroke or TIA, previous, %	3.2	6.7	5.4
Index finger circumference*, mm	75 (69–81)	71 (68–79)	74 (68–80)
Years since acromegaly diagnosis*	6.5 (2.9–12.5)	8.4 (4.0–14.7)	7.7 (3.6–13.7)
Pituitary surgery, %	85	92	89
Pituitary radiotherapy, %	18	18	18
Current medical therapy for acromegaly, %	37	27	31
Somatostatin analogue, %	34	23	27
Dopamine agonist, %	2.1	3.7	3.1
Pegvisomant, %	8.4	7.9	8.1

\* median (25th–75th percentile)